Subject    :    [2017 Apr;41(2)] Role of NO/VASP Signaling Pathway against Obesity-Related Inflammation and Insulin Resistance
Writer KDA
Date 2017-07-06 10:58:54 Hit 6,322
Diabetes Metab J. 2017 Apr;41(2):89-95. English.
Published online Nov 15, 2016.  https://doi.org/10.4093/dmj.2017.41.2.89 
Copyright © 2017 Korean Diabetes Association
   
Role of NO/VASP Signaling Pathway against Obesity-Related Inflammation and Insulin Resistance
Yu Mi Kang,1 Francis Kim,2 and Woo Je Lee1
1Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
2Department of Medicine, Diabetes and Obesity Center of Excellence, University of Washington, Seattle, WA, USA.

Corresponding author: Woo Je Lee. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea. Email: lwjatlas@amc.seoul.kr 
 
Received September 08, 2016; Accepted October 26, 2016.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

 
Abstract

Obesity has quickly become a worldwide pandemic, causing major adverse health outcomes such as dyslipidemia, type 2 diabetes mellitus, cardiovascular disease and cancers. Obesity-induced insulin resistance is the key for developing these metabolic disorders, and investigation to understand the molecular mechanisms involved has been vibrant for the past few decades. Of these, low-grade chronic inflammation is suggested as a critical concept in the development of obesity-induced insulin resistance, and the anti-inflammatory effect of nitric oxide (NO) signaling has been reported to be linked to improvement of insulin resistance in multiple organs involved in glucose metabolism. Recently, a body of evidence suggested that vasodilatory-stimulated phosphoprotein (VASP), a downstream mediator of NO signaling plays a crucial role in the anti-inflammatory effect and improvement of peripheral insulin resistance. These preclinical studies suggest that NO/VASP signaling could be an ideal therapeutic target in the treatment of obesity-related metabolic dysfunction. In this review, we introduce studies that investigated the protective role of NO/VASP signaling against obesity-related inflammation and insulin resistance in various tissues.

   
Keywords:
Adipose tissue; Chronic inflammation; Endothelium, vascular; Insulin resistance; Liver; Macrophages; Nitric oxide; Obesity; Vasodilator-stimulated phosphoprotein

Articles - Reviews in DMJ
No. Subject Date Hit ↓
197 [2017 Jun;41(3)] Satisfaction Survey on Information Technology-Based... 2017-07-06 6,673
196 [2017 Jun;41(3)] The Effect of 12 Weeks Aerobic, Resistance, and Com... 2017-07-06 6,649
195 [2017 Jun;41(3)] Impact of Gender on the Association between Low Ser... 2017-07-06 6,516
194 [2017 Jun;41(3)] Physician-Directed Diabetes Education without a Med... 2017-07-06 6,196
193 [2017 Jun;41(3)] Knowledge, Attitude, and Practice of Iranian Intern... 2017-07-06 6,327
192 [2017 Jun;41(3)] Comparison of Antidiabetic Regimens in Patients wit... 2017-07-06 6,409
191 [2017 Jun;41(3)] Diabetes Prevention in Australia: 10 Years Results ... 2017-07-06 6,299
190 [2017 Jun;41(3)] Comprehensive Approach for Managing the Older Perso... 2017-07-06 5,974
189 [2017 Apr;41(2)] A Cutoff for Age at Menarche Predicting Metabolic S... 2017-07-06 5,920
188 [2017 Apr;41(2)] Addition of Ipragliflozin to Metformin Treatment in... 2017-07-06 6,273

목록

Gets the previous 5 pages.   Go to previous page.  [1]   2   3   4   5     Go to next page. Gets the next  5 pages.